Article Versions Notes

Schilhabel A, Walter PJ, Cramer P, von Tresckow J, Kohlscheen S, Szczepanowski M, Laqua A, Fischer K, Eichhorst B, Böttcher S, et al. CD20 Expression as a Possible Novel Prognostic Marker in CLL: Application of EuroFlow Standardization Technique and Normalization Procedures in Flow Cytometric Expression Analysis. Cancers. 2022; 14(19):4917. https://doi.org/10.3390/cancers14194917

Schilhabel, Anke, Peter Jonas Walter, Paula Cramer, Julia von Tresckow, Saskia Kohlscheen, Monika Szczepanowski, Anna Laqua, Kirsten Fischer, Barbara Eichhorst, Sebastian Böttcher, and et al. 2022. "CD20 Expression as a Possible Novel Prognostic Marker in CLL: Application of EuroFlow Standardization Technique and Normalization Procedures in Flow Cytometric Expression Analysis" Cancers 14, no. 19: 4917. https://doi.org/10.3390/cancers14194917

Schilhabel, A., Walter, P. J., Cramer, P., von Tresckow, J., Kohlscheen, S., Szczepanowski, M., Laqua, A., Fischer, K., Eichhorst, B., Böttcher, S., Schneider, C., Tausch, E., Brüggemann, M., Kneba, M., Hallek, M., & Ritgen, M. (2022). CD20 Expression as a Possible Novel Prognostic Marker in CLL: Application of EuroFlow Standardization Technique and Normalization Procedures in Flow Cytometric Expression Analysis. Cancers, 14(19), 4917. https://doi.org/10.3390/cancers14194917